DBVT DBV TECHNOLOGIES SA US FDA Inspections 8-K Filing 2023 - Financial Condition and Other Events DBV Technologies S.A. had $192.3 million of cash and cash equivalents as of March 31, 2023. The company announced the regulatory path for investigational Viaskin Peanut 250 g patch in toddlers with peanut allergy.Get access to all SEC 8-K filings of the DBV TECHNOLOGIES SA